自身免疫性肝炎(AIH)是肝硬化的常见原因。为了确定AIH患者口腔微生物组的特征,我们收集了204份唾液样本,包括68例AIH患者和136例健康对照,并在筛选后进行微生物MiSeq测序.将所有样本随机分为发现队列(46个AIH和92个HCs)和验证队列(22个AIH和44个HCs)。此外,我们从杭州收集了12例AIH患者的样本进行跨区域验证.我们描述了AIH患者的口腔微生物组特征并建立了诊断模型。在AIH组中,口腔微生物组多样性显著增加。两组之间的微生物群落存在显着差异。七个属,主要是梭杆菌,放线菌和Capnocytophaga,在HC组中占主导地位,而51属,链球菌,Veillonella和Leptotrichia,在AIH组中富集。值得注意的是,我们发现了23个基因功能,包括膜运输,碳水化合物代谢,AIH中占主导地位的糖脂代谢和HCs中占主导地位的31种基因功能。我们进一步研究了口腔微生物组和临床参数之间的相关性。通过随机森林模型计算出最佳的5个微生物标记,在发现队列中,46AIH和92HCs之间的区分潜力达到99.88%,在验证队列中达到100%。重要的是,在跨区域验证队列中,区分潜力达到95.55%.总之,这项研究首次描述了AIH患者的口腔微生物组特征,并报道了AIH的诊断模型的成功建立和微生物标志物的跨区域验证.重要的是,针对口腔微生物群的生物标志物可能能够作为AIH的强大且无创的诊断工具.
Autoimmune hepatitis (AIH) is a common cause of liver cirrhosis. To identify the characteristics of the oral microbiome in patients with AIH, we collected 204 saliva samples including 68 AIH patients and 136 healthy controls and performed microbial MiSeq sequencing after screening. All samples were randomly divided into discovery cohorts (46 AIH and 92 HCs) and validation cohorts (22 AIH and 44 HCs). Moreover, we collected samples of 12 AIH patients from Hangzhou for cross-regional validation. We described the oral microbiome characteristics of AIH patients and established a diagnostic model. In the AIH group, the oral microbiome diversity was significantly increased. The microbial communities remarkably differed between the two groups. Seven genera, mainly Fusobacterium, Actinomyces and Capnocytophaga, were dominant in the HC group, while 51 genera, Streptococcus, Veillonella and Leptotrichia, were enriched in the AIH group. Notably, we found 23 gene functions, including Membrane Transport, Carbohydrate Metabolism, and Glycerolipid metabolism that were dominant in AIH and 31 gene functions that prevailed in HCs. We further investigated the correlation between the oral microbiome and clinical parameters. The optimal 5 microbial markers were figured out through a random forest model, and the distinguishing potential achieved 99.88% between 46 AIH and 92 HCs in the discovery cohort and 100% in the validation cohort. Importantly, the distinguishing potential reached 95.55% in the cross-regional validation cohort. In conclusion, this study is the first to characterize the oral microbiome in AIH patients and to report the successful establishment of a diagnostic model and the cross-regional validation of microbial markers for AIH. Importantly, oral microbiota-targeted biomarkers may be able to serve as powerful and noninvasive diagnostic tools for AIH.